Cargando…
Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling
Background: Chemotherapy remains a primary treatment method for advanced pancreatic cancer. However, chemotherapy resistance can influence the therapeutic effect of pancreatic cancer. The resistance mechanism of chemotherapeutic agents such as gemcitabine, which is an agent typically used to treat p...
Autores principales: | Wang, Bili, Shen, Can, Li, Yang, Zhang, Ting, Huang, Hui, Ren, Jun, Hu, Zhengjun, Xu, Jian, Xu, Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6645696/ https://www.ncbi.nlm.nih.gov/pubmed/31410021 http://dx.doi.org/10.2147/OTT.S208924 |
Ejemplares similares
-
Gemcitabine-loaded albumin nanospheres (GEM-ANPs) inhibit PANC-1 cells in vitro and in vivo
por: Li, Ji, et al.
Publicado: (2013) -
Biodegradable Polymersomes for the Delivery of Gemcitabine to Panc-1 Cells
por: Sood, Nimil, et al.
Publicado: (2013) -
Oridonin nanosuspension was more effective than free oridonin on G(2)/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line
por: Qi, Xiaoli, et al.
Publicado: (2012) -
LRP-1 Promotes Cancer Cell Invasion by Supporting ERK and Inhibiting JNK Signaling Pathways
por: Langlois, Benoit, et al.
Publicado: (2010) -
Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance
por: Liu, Xi, et al.
Publicado: (2020)